이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Oncology Institute 과거 수익 실적

과거 기준 확인 0/6

Oncology Institute의 수입은 연평균 -72.3%의 비율로 감소해 온 반면, Healthcare 산업은 수입이 연평균 5.6%의 비율로 증가했습니다. 매출은 연평균 21.3%의 비율로 증가해 왔습니다.

주요 정보

-72.3%

수익 성장률

-74.9%

EPS 성장률

Healthcare 산업 성장	8.5%
매출 성장률	21.3%
자기자본 수익률	-176.7%
순이익	-17.4%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 05

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

Mar 21

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

Mar 05

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Nov 10

The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit

Aug 09

Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings

May 18

Companies Like Oncology Institute (NASDAQ:TOI) Are In A Position To Invest In Growth

Mar 16

The Oncology Institute: Capitalizing On Clinical Research Contracts

Dec 22

수익 및 비용 분석

Oncology Institute 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:TOI 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	343	-60	113
31 Dec 23	324	-68	114
30 Sep 23	310	-61	113
30 Jun 23	293	-50	117
31 Mar 23	274	-40	120
31 Dec 22	252	0	120
30 Sep 22	233	-1	137
30 Jun 22	221	-2	118
31 Mar 22	210	6	100
31 Dec 21	203	-11	83
30 Sep 21	200	-6	50
30 Jun 21	195	-3	46
31 Mar 21	192	-5	44
31 Dec 20	188	-14	42
31 Dec 19	155	-4	30
31 Dec 18	113	-2	17

양질의 수익: TOI 은(는) 현재 수익성이 없습니다.

이익 마진 증가: TOI 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: TOI 은(는) 수익성이 없으며 지난 5년 동안 연간 72.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 TOI 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: TOI 은(는) 수익성이 없어 지난 해 수익 성장을 Healthcare 업계( 15.1% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: TOI 현재 수익성이 없기 때문에 마이너스 자본 수익률( -176.67% )을 갖습니다.

Oncology Institute 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.33 loss in 1Q 2023)

The Oncology Institute, Inc. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released: US$0.92 loss per share (vs US$0.001 profit in FY 2022)

The Oncology Institute, Inc. to Report Q4, 2023 Results on Mar 27, 2024

the Oncology Institute Reports Goodwill Impairment Charge for the Nine Months Ended 2023

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.03 loss in 3Q 2022)

Recent updates

The Oncology Institute, Inc. Receives A Written Notice from the Nasdaq Stock Market LLC

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.33 loss in 1Q 2023)

The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Year 2024

The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

The Oncology Institute, Inc., Annual General Meeting, Jun 13, 2024

The Oncology Institute, Inc. to Report Q1, 2024 Results on May 14, 2024

New minor risk - Market cap size

The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer

Full year 2023 earnings released: US$0.92 loss per share (vs US$0.001 profit in FY 2022)

The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2024

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

The Oncology Institute, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

New major risk - Share price stability

Key Executive recently bought US$127k worth of stock

New minor risk - Market cap size

Vice Chairman notifies of intention to sell stock

Vice Chairman notifies of intention to sell stock

Vice Chairman notifies of intention to sell stock

New major risk - Revenue and earnings growth

the Oncology Institute Reports Goodwill Impairment Charge for the Nine Months Ended 2023

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.03 loss in 3Q 2022)

The Oncology Institute, Inc. to Report Q3, 2023 Results on Nov 08, 2023

The Oncology Institute, Inc. Names Jeremy Castle as Chief Operations Officer

New major risk - Revenue and earnings growth

The Oncology Institute Regains Compliance with Nasdaq Listing Requirements

The Oncology Institute, Inc. Appoints Jeremy N. Castle as Chief Operations Officer

The Oncology Institute, Inc. (NasdaqCM:TOI) announces an Equity Buyback for 2,000,000 shares, for $2 million.

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.062 loss in 2Q 2022)

The Oncology Institute, Inc. Reaffirms Earnings Guidance for the Full Year 2023

New minor risk - Shareholder dilution

The Oncology Institute, Inc. (NasdaqCM:TOI) announces an Equity Buyback for 5,000,000 shares, for $3.75 million.

The Oncology Institute, Inc. Appoints Brad Hively as Vice Chair of the Board

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Southland Radiation Oncology Network.

the Oncology Institute, Inc. Announces Departure of Matthew Miller, M.D. as Chief Operating Officer Effective June 16, 2023

The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.41 loss per share (vs US$0.21 profit in 1Q 2022)

The Oncology Institute, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2023

The Oncology Institute, Inc. Patient to Be Treated with Promising Therapy for Metastatic Ovarian Cancer

Full year 2022 earnings released: EPS: US$0.023 (vs US$0.17 loss in FY 2021)

The Oncology Institute, Inc. to Report Q4, 2022 Results on Mar 09, 2023

Chief Operating Officer recently bought US$70k worth of stock

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Practice of Dr. Labib Hashimi.

President exercised options to buy US$382k worth of stock.

The Oncology Institute, Inc. Announces Diona Simoneit to Resign as Chief Accounting Officer and Principal Accounting Officer

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired The South Miami Clinic.

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

The Oncology Institute, Inc. Revises Earnings Guidance for the Year 2022

Independent Director notifies of intention to sell stock

The Oncology Institute, Inc. to Report Q3, 2022 Results on Nov 09, 2022

the Oncology Institute, Inc. Announces Executive Appointments

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired BROWARD ONCOLOGY ASSOCIATES.

The Oncology Institute Enrolls Nation's First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib

The Oncology Institute, Inc. Appoints Two New Board Members

Second quarter 2022 earnings released: US$0.062 loss per share (vs US$0.049 profit in 2Q 2021)

The Oncology Institute, Inc. Provides Revenue Guidance for 2022

The Oncology Institute, Inc. announced that it has received $110 million in funding

The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit

The Oncology Institute, Inc. (NasdaqCM:TOI) acquired Practice of Dr. Nutan Parikh.

The Oncology Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022

M33 Growth, LLC Engages in Discussion with The Oncology Institute

Havencrest Healthcare Engages in Discussion with The Oncology Institute

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

The Oncology Institute, Inc., Annual General Meeting, Jul 14, 2022

Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings

Founder & Chief Clinical Officer recently sold US$9.6m worth of stock